Shilpa Medicare

₹953.65As of Sun 8 Nov 2026, 12:00 UTC

NSE:SHILPAMEDHealthcare

Country India

PE (Fwd) 70.29

TSR 10Y CAGR 12.42%

Div yield 0.06%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.37

PE TTM 76.65

TSR TTM 170.44%

Mkt cap ₹182.0B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹1,057

10.82%

(93.32%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

15.40

Revenue₹B

—

11.47

10.52

11.53

12.88

15.40

16.30

7.65%

19.60

Revenue growth%

—

(8.31)

9.64

11.69

19.60

5.80

10.67

—

66.13

Gross margin%

—

62.38

56.22

61.54

64.74

66.13

65.94

62.38

17.07

Operating margin%

—

10.50

(0.51)

11.20

15.16

17.07

16.72

11.20

15.80

Net margin%

—

5.29

(3.09)

2.76

6.08

15.80

15.54

5.29

76.65

P/E ratio (avg)x

—

73.36

—

92.79

86.80

30.30

73.67

80.08

—

70.95

EV/EBITx

—

36.96

—

22.90

34.81

28.05

68.44

31.43

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

12.44

EPS₹

—

3.63

(1.87)

1.84

4.02

12.44

12.94

36.05%

—

209.66

EPS growth%

—

(151.61)

197.97

118.83

209.66

4.05

158.40

—

100

—

Bookvalue per sh₹

—

FCF per share₹

—

0.60

Dividend per sh₹

—

0.55

—

0.50

0.60

0.66

2.20%

—

0.06

Div yield (avg)%

—

0.21

—

0.14

0.16

0.07

0.16

—

4.82

Payout ratio%

—

15.15

—

12.44

4.82

5.09

8.63

—

195.6

Shares (diluted)M

—

167.1

173.6

194.9

195.6

◌195.6

4.02%

(0.37)

Buyback yield%

—

(3.91)

—

(12.24)

(0.37)

◌—

(2.14)

—

D/E ratiox

—

186.5

Enterprise value₹B

—

44.50

25.22

29.58

67.95

73.73

186.5

13.45%

—

LT debt₹M

—

Peers (US$1.952B)

Cap (US$)

Alembic Pharmaceutical…

2.016B

22.43x

Alivus Life Sciences…

1.924B

27.04x

Caplin Point Laborator…

1.922B

27.28x

Porton Pharma Solution…

1.947B

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

5.641

2.584

Own earn%

—

Sh yield%

(0.31)

(2.06)

Owners

Insiders/Inst%

48.51

19.61

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

4/5

Revenue growth years

3/4

EPS growth years

3/4

Dividend streakyrs

Op margin range%

−1–17

$1 testx

—

Incr. ROIC%

—

Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹15.40B

7.65%

1.00×

Cost of revenue

₹5.217B

4.86%

0.90×

Operating expenses

₹7.557B

6.16%

0.95×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m